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Dendritic cells (DC) are professional antigen-presenting cells (APC) of the immune system, uniquely able to prime naı ¨ve T-cell
responses. They are the focus of a range of novel strategies for the immunotherapy of cancer, a proportion of which include treating
DC with ionising radiation to high dose. The effects of radiation on DC have not, however, been fully characterised. We therefore
cultured human myeloid DC from CD14
þ precursors, and studied the effects of ionising radiation on their phenotype and function.
Dendritic cells were remarkably resistant against radiation-induced apoptosis, showed limited changes in surface phenotype, and
mostly maintained their endocytic, phagocytic and migratory capacity. However, irradiated DC were less effective in a mixed
lymphocyte reaction, and on maturation produced significantly less IL-12 than unirradiated controls, while IL-10 secretion was
maintained. Furthermore, peptide-pulsed irradiated mature DC were less effective at naı ¨ve T-cell priming, stimulating fewer effector
cells with lower cytotoxicity against antigen-specific targets. Hence irradiation of DC in vitro, and potentially in vivo, has a significant
impact on their function, and may shift the balance between T-cell activation and tolerisation in DC-mediated immune responses.
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Dendritic cells (DC) are the most potent of antigen-presenting cells
(APC), unique in their ability to prime a naı ¨ve T-cell response
(Banchereau and Steinman, 1998; Guermonprez et al, 2002).
Immature DC (IDC) acquire antigen in the periphery and, in
response to a range of activation or maturation signals, migrate to
lymph nodes as mature DC (MDC), where they interact with
responsive T cells (Rescigno et al, 1997). This interaction can
result in immune tolerisation or activation, depending on the
phenotype and functional state of involved DC. Effective initiation
of an acquired immune response requires DC which are fully
activated, expressing high levels of MHC and co-stimulatory
molecules, and secreting the cytokines required to prime a potent
helper T-cell response (particularly IL-12) (Steinman et al, 2003).
The effects of ionising radiation on DC are largely unknown,
with limited data available. Irradiated IDC were less efficient at
stimulating T-cell proliferation, with or without antigen, in an
autologous mixed lymphocyte reaction (MLR) (Anton et al, 1998;
Cao et al, 2004), while a recent report showed a differential effect
of irradiation on antigen presentation by mouse DC, with
impairment of T-cell priming against endogenously processed
antigen, but an enhanced response against exogenously pulsed
peptide (Liao et al, 2004).
The functional consequences of irradiating human DC are
important in several contexts. The ability to culture DC from blood
products ex vivo has led to a rapid expansion in clinical
immunotherapy protocols using DC to activate or nullify
antigen-specific immune responses (Melcher et al, 2002). The
majority of these approaches are for the immunotherapy of cancer,
and involve loading DC with tumour-associated antigens prior to
vaccination of the patient. There is a wealth of pre-clinical data to
support such strategies, and early studies have shown some
promise (Timmerman and Levy, 1999). Alternatively, antigen-
loaded DC can be used ex vivo to expand specific effector T-cell
populations for subsequent adoptive transfer back into patients
(Yee et al, 2000; Szmania et al, 2001; Ho et al, 2003). During many
of these applications, DC are irradiated with X-rays or gamma
sources, often to high doses (typically 30Gy) in a single fraction. In
some cases, such as irradiation of DC/tumour cell co-cultures or
hybrids (Gong et al, 1997; Celluzzi and Falo, 1998), this treatment
is rationally designed to prevent any outgrowth of viable tumour
cells from within the proposed vaccine. In others, such as
vaccination with tumour lysate-loaded DC (Fields et al, 1998),
and priming of T cells in vitro for subsequent adoptive transfer
(Szmania et al, 2001), the purpose of DC irradiation is less clear
and potentially deleterious. Regardless of application, irradiation
of DC is often assumed to have no bearing on subsequent DC/T-
cell interactions or immune priming and to be immunologically
neutral. However, this assumption has not been rigorously
tested.
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in patients may also be functionally important. Clinical radio-
therapy is regarded as being broadly immunosuppressive due to
effects on sensitive immune cell target populations such as
lymphocytes (Illidge, 1998), although radiation may also stimulate
immunity by inducing danger signals in association with tumour
cell death (McBride et al, 2004). Although the mechanisms
underlying interaction between radiation and the immune system
are poorly understood, radiotherapy has been intentionally
combined with immunotherapy to enhance tumour-specific
immune activation in preclinical models (Chakravarty et al,
1999; Teitz-Tennenbaum et al, 2003; Milas et al, 2004). Optimisa-
tion of such protocols, which rely on endogenous or ex vivo
cultured DC for their success, may be facilitated by an improved
understanding of the effects of ionising radiation on DC effector
function.
Therefore, we have compared irradiated human myeloid DC
with untreated controls to characterise the consequences of
irradiation on ex vivo DC applications or potential in vivo
treatments. We show that human DC are resistant to radiation-
induced apoptosis and show few changes in phenotypic surface
markers. Irradiated DC maintain their ability to take up antigen
and migrate in vitro, but are less potent in an allogeneic MLR.
Importantly, irradiated DC alter the balance of the cytokines they
secrete on activation, by reducing their IL-12 production while
maintaining IL-10. Irradiated DC pulsed with a tumour antigen
peptide prime fewer, less potent cytotoxic T cells (CTL) than
unirradiated controls. These effects of irradiation occur down-
stream of the translocation of RelB to the nucleus, an event
associated with DC maturation. These data have implications for
the application of DC both in vitro and in vivo, and suggest that
direct DC irradiation should be avoided when trying to generate
antigen-specific responses.
MATERIALS AND METHODS
Dendritic cell culture and characterisation
Dendritic cells were generated from human peripheral blood
mononuclear cells (PBMC), according to protocols previously
published (Pickl et al, 1996; Romani et al, 1996). Briefly, adherent
or CD14
þ-selected monocytes were cultured in RPMI 1640 (Gibco
BRL, Paisley, UK) supplemented with 10% vv
 1 FCS, 1% vv
 1
L-glutamine (Gibco BRL, Paisley, UK), 800Uml
 1 GMCSF
(Schering-Plough, Cork, Ireland) and 500Uml
 1 IL-4 (R&D
Systems, Abingdon, UK) for 5 days. Where indicated, DC were
irradiated to 30Gy at 2.7Gymin
 1 (GammaCell Elite 1000
137Cs
source) and maturation induced by addition for 24h of 100ngml
 1
LPS (Sigma, Poole, Dorset, UK). Anti-human HLA-DR-PE, CD80-
PE, CD83-PE, CD86-PE, CD1a-PE and CCR7-PE (BD Bioscience
Pharmingen, Cowley, Oxford, UK) were used for phenotypic
characterisation of DC. All samples were counted and analysed
using a FACSCaliber and CellQuest Pro software
r 2000 (Becton,
Dickinson and Company, Hertfordshire, UK).
Apoptotis assay
Apoptosis was quantified using the Annexin-V FITC apoptosis
detection kit (BD Biosciences Pharmingen, Cowley, Oxford, UK),
according to the manufacturer’s instructions.
Dendritic cell functional analysis: fluid phase endocytosis,
phagocytosis, migration and allogeneic MLR
Endocytosis by DC was assayed by incubation with DQtBSA
(Molecular Probes Inc., Eugene, OR, USA), a quenched BODIPY
s
fluorescent dye-labelled molecule that releases fluorophores by
intracellular hydrolysis. Relative fluorescence is quantifiable by
FACS analysis (excitation and emission maxima of 505 and
515nm, respectively).
Phagocytosis of tumour cells by DC was assessed by fluorescent
labelling of tumour cells prior to co-incubation. SW480 tumour
cells were dyed for 45min at 371C with 1mM CellTrackert red
(Molecular Probes Inc, Eugene, Oregon, USA), rinsed thoroughly,
and co-cultured with DC for 4h. The cells were viewed by
fluorescent microscopy to confirm the presence of a stained
population, which was quantified by FACS analysis.
Live imaging and migration of DC was assayed in 35mm glass-
bottomed dishes (Bibby Sterilin, Stone, UK) coated with 50mgml
 1
fibronectin (Sigma, Poole, Dorset, UK). Dendritic cells were seeded
at 3 10
5 per dish in pre-warmed media supplemented with 20mM
HEPES and transferred to a Zeiss Axiovert 200 inverted micro-
scope with an enclosed, heated stage (Solent Scientific Ltd,
Portsmouth, UK) with a maintained temperature of 371C and left
for 30–45min prior to filming. Time-lapse phase-contrast images
were captured using an  20 dry lens at 15s intervals for a
duration of 30min with a Hamamatsu Orca 2 ER camera using
2 2 binning and exposure times of less than 500msframe
 1.
Microscope, camera and shutters were controlled by Kinetic
Imaging AQM 6 software. All cells remaining within the field of
view for the full 30min were tracked and analysed for distance
travelled and velocity using Kinetic Imaging Motion Analysis
software.
To assess allogeneic T-cell proliferation in a MLR, day 5 DC were
irradiated/matured for 24h prior to assay. Allogeneic lymphocytes
(2 10
5 per well) were plated in U-bottomed 96-well plates.
Dendritic cells were serially diluted and added at ratios ranging
from 1:10 to 1:160 DC to responding lymphocytes and co-
incubated for 5 days.
3H-thymidine (0.5mCi per well) was added
for 18h before harvesting (TOMTEC Harvester 96 Mach IIIM) onto
filter mats and counting (Wallac Jet 1450 Microbeta scintillation
counter and Microbeta windows software, Wallac, Oy Finland).
Cytokine detection
Levels of IL-10 and IL-12 p70 were measured by ELISA using
matched paired antibodies (BD Biosciences, Pharmingen, Cowley,
Oxford, UK) according to the manufacturer’s instructions.
Generation of CTL and cytotoxicity assay
RPMI 1640 supplemented with 7.5% vv
 1 FCS, 1% vv
 1
L-glutamine, 1% vv
 1 non-essential amino acids (Gibco BRL,
Paisley, UK), 1% vv
 1 sodium pyruvate (Gibco BRL, Paisley, UK),
1% vv
 1 hepes (Gibco BRL, Paisley, UK) and 20mM 2-b
mercaptoethanol was used for all CTL cultures. Irradiated or
unirradiated HLA-A2þMDC were pulsed with HLA-A2-restriced
MelanA/MART-127–35 (AAGIGILTV) peptide for 1h and mixed
with autologous PBMCs at a ratio of 1:10–1:30. IL-7 (5ngml
 1;
R&D systems, Abingdon, UK) was added to cultures from day 1
and throughout; 30Uml
 1 IL-2 (R&D systems, Abingdon, UK) was
added on day 3 only. T cells were re-stimulated twice at weekly
intervals, each time with peptide-pulsed DC in identical propor-
tions. At 21 days, cells were harvested and cytotoxicity of CTL
measured using a standard 4h
51Cr release assay. Briefly, T2 target
cells were pulsed with 4mgml
 1 MART-1, irrelevant or no peptide
and labelled with 100mCi Cr
51 for 1h, then washed three times and
co-cultured with CTL at different effector:target ratios. To reduce
background/nonspecific killing, the same number of unlabelled
K562 cells as target cells was added to each condition. After 4h,
cells were spun down and 50ml of supernatant was transferred to
scintillation plates (Packard Biosciences, Groningen, The Netherlands)
and dried overnight before counting. Percentage lysis was calculated
using the following formula:
% lysis¼100 (sample cpm spontaneous cpm)/(maximum
cpm spontaneous cpm).
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Nuclear extracts of DC were prepared as described previously
(Schreiber et al, 1989). Briefly, DC were washed with PBS and
resuspended at a maximum of 1 10
6 cells in 400ml of cold buffer
A (10mM HEPES, pH 7.9; 10mM KCl; 0.1mM EDTA; 0.1mM EGTA;
1m M DTT; 0.5mM PMSF). The cells were allowed to swell for
15min on ice, before adding 25ml of 10% Igepal solution. The
tubes were vortexed thoroughly, centrifuged and the supernatant
removed. The nuclear pellet was resuspended in 50ml cold buffer B
(20mM HEPES, pH 7.9; 0.4M NaCl; 1mM EDTA; 1mM EGTA; 1mM
DTT; 1mM PMSF) and vigorously shaken for 15min at 41C before
centrifugation. The soluble nuclear fraction was removed,
aliquoted and stored at  801C. Nuclear protein concentration
was determined by Bradford Assay and 10mg protein samples were
resolved by 10% SDS–polyacrylamide gel electrophoresis before
transfer onto nitrocellulose membrane. The blots were probed with
anti-RelB rabbit polyclonal antibody (Santa Cruz, CA, USA) and
horseradish peroxidase-conjugated secondary antibody (Dako
Cytomation, CA, USA) before visualisation with SuperSignal West
Pico Chemiluminescent Substrate (Pierce Biotecnology, IL, USA).
After antibody staining, the blots were stained with Ponceau S
(Sigma, Poole, Dorset, UK) to confirm equal protein loading.
Statistical analysis
Comparisons of irradiated vs control DC were carried out by
paired t-test; pooled cytotoxicity data were compared using an
F test. The P-value was considered statistically significant if
Pp0.05. Error bars are s.e.m.
RESULTS
Dendritic cells are resistant to radiation-induced apoptosis
Figure 1A shows the radiosensitivity of immature and mature
human DC cultured from CD14
þ precursors at 24h following a
single 30Gy treatment. Annexin/PI staining reveals no significant
changes in apoptotic (Annexin þve, PI  ve; lower right
quadrant), or necrotic (Annexin þve, PI þve; upper right
quadrant) populations with irradiation, showing that DC do not
undergo a rapid interphase death. As a positive control, extensive
apoptotic death post-radiation of the murine lymphoma cell line
EL4 is also shown. Figure 1B confirms this resistance of DC over
longer time periods by trypan blue exclusion. Immature DC show a
transient expansion in number over the first 24h of culture but
then, as anticipated, all differentiated DC lose viability over time.
While in this experiment IDC cell loss was slightly faster on
irradiation, pooled data from five donors showed no statistically
significant difference in the rate of cell death between irradiated
and untreated cultures of either MDC or IDC (data not shown).
Similar resistance was seen at lower doses (2 and 8Gy – data not
shown). These data show that differentiated DC divide little and do
not rapidly apoptose following radiation.
Irradiated DC show limited changes in surface phenotype,
but are less stimulatory in an allogeneic MLR
We next studied the surface phenotype of IDC and MDC, with and
without irradiation. A range of surface markers for DC matura-
tional state was examined, comprising MHC class I and II, CD40,
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Figure 1 Dendritic cell death following radiation. Apoptosis/necrosis of DC was assessed by FACS analysis after incubation with Annexin-V FITC and
propidium iodide (A). No significant difference was seen in the apoptotic (lower right quadrant) or necrotic (upper right quadrant) populations of IDC or
MDC730Gy at 24h post treatment, in contrast to the significant early apoptotic death of radiosensitive EL4. (B) Dendritic cell viability was further assessed
by seeding cells at constant density, and counting live cells daily using trypan blue exclusion. No statistical difference was found in the rate of cell death
between irradiated (’) or nonirradiated (E) controls for IDC or MDC. Data shown are representative of five similar experiments.
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changes seen were in surface levels of CD86, after irradiation to
30Gy. As shown in Figure 2, basal levels of CD86 on IDC were
increased with irradiation (although absolute levels remained low),
while high CD86 expression on MDC was decreased following
30Gy. Due to the variable DC phenotype characteristic of
individual human donors, data are shown as change in median
fluorescence for five separate donors (A and C), and as a
representative histogram for one donor (B and D). No significant
alteration was seen in the expression pattern of (i) any other
marker on IDC or MDC at doses of 2, 8 and 30Gy, or (ii) CD86 at
doses less than 30Gy (data not shown). These limited changes in
surface phenotype of DC on irradiation are consistent with a recent
report on irradiation of murine DC (Liao et al, 2004).
Since the ability of DC to stimulate proliferation of allogeneic T
cells is often used as a surrogate marker of their activation state,
we next assessed the potency of irradiated DC in a standard
allogeneic MLR. Irradiation of both IDC and MDC to 30Gy
significantly reduced T-cell proliferation in these assays over a
range of stimulator:responder ratios, consistent with impaired
DC/T-cell interaction following DC radiation (Figure 2E and F).
This reduction is consistent with less co-stimulatory CD86 on
irradiated MDC, but occurs despite increased (though still
relatively low) levels of CD86 on IDC. This suggests that factors
other than CD86 expression are involved in determining
the potency of DC in an MLR, and implies that irradiation
may compromise DC/T-cell interactions during immune
priming.
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Figure 2 CD86 expression and MLR activity of irradiated dendritic cells. Changes in surface phenotype of DC were assessed 24h post treatment by
FACS analysis. Expression of the co-stimulatory molecule CD86 was significantly upregulated on IDC after irradiation (Po0.04), and downregulated on
MDC (Po0.02), though levels on remained 410 fold less on IDC vs MDC. Data shown as MFI of five donors (A, C), and as a representative histogram for
one donor (B, D). Mixed lymphocyte reaction: irradiated (dark bars) or control (light bars) IDC (E) and MDC (F) were incubated with responder allogeneic
T cells at different ratios and incubated for 5 days before the addition of
3H-thymidine for 18h, followed by harvesting and counting. Data are representative
of four similar experiments.
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and migratory capacity
We next examined the endocytic, phagocytic and migratory
capacity of irradiated vs unirradiated DC, to test whether radiation
is likely to effect antigen uptake by DC, or their ability to migrate
from sites of antigen acquisition to lymph nodes for interaction
with reactive T cells. High endocytic/phagocytic capacity is
characteristic of IDC, while greater motility is a feature of MDC.
Figure 3A shows fluid phase endocytosis by DC of albumin labelled
with BODIPY, a fluorescent dye which is quenched extracellularly
and hence specifically demonstrates cell uptake. Fluorescence
levels were slightly reduced (though still high) on irradiation of
IDC, while 30Gy did not affect uptake by MDC. When phagocytic
capacity by irradiated DC was assessed using uptake of
fluorescently labelled human SW480 tumour cells, there was again
reduced (though still significant) uptake on irradiation by IDC,
and no change for MDC (Figure 3B). Hence antigen uptake by
MDC, and to a lesser extent IDC, is largely maintained following
irradiation.
To study the in vitro migratory capacity of human DC, we
quantified the motility of IDC and MDC on fibronectin-coated
glass-bottomed dishes. Consistent with published data (De Vries
et al, 2003), we found increased migration of MDC compared to
IDC at 24 and 48h with or without irradiation (Figure 3C). The
only significant difference in the distance DC travelled after
radiation was an increase in migration of IDC at 24h, though this
effect was lost at 48h. MDC motility was unaffected by irradiation
at either time point. Overall, these data suggest that irradiated DC
will be effective at antigen acquisition and migration to lymph
nodes for potential interaction with T cells.
Irradiated mature DC secrete less IL-12, but maintain IL-10
production
The cytokines produced by activated DC are key determinants in
the generation of T-cell-mediated immunity. Therefore, we
measured the cytokines produced by irradiated or unirradiated
DC matured with LPS. No cytokines were detected from
unstimulated IDC, with or without irradiation (data not shown).
Figure 4 shows that MDC secrete both IL-12 (a Th1 cytokine) and
IL-10 (Th2) on activation, consistent with previous reports (Qi
et al, 2003). However, the IL-12/IL-10 balance was different after
DC irradiation, with IL-12 production significantly reduced
(Figure 4A), while IL-10 was maintained (Figure 4B). The same
impaired secretion of IL-12, but not IL-10, was seen when OK432
(Nakahara et al, 2003) was used as an alternative maturation factor
(data not shown). Since cytokine production by activated human
DC can again be variable between donors, Figure 4 illustrates the
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Figure 3 Endocytosis, phagocytosis and motility of irradiated DC. Fluid-phase endocytosis by DC was measured following incubation with BODIPY-
labelled BSA (A). Dendritic cell were incubated with the dye for 30min at either 371Co ra t0 1C as a negative control (pale grey histogram). Uptake shown
by shift in fluorescence for unirradiated DC (dark grey histogram) vs irradiated DC (black histogram). Phagocytosis was similarly measured by uptake of
fluorescently labelled whole tumour cells, with untreated DC alone as the control (B). These data are representative of three similar experiments. (C)
Tracking (30-min) of IDC and MDC 24 and 48h post irradiation. Each data point represents the distance travelled by an individual cell, with the horizontal
bar showing the mean for the group.
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IL-6, TNF-a, IFN-g) were no different between irradiated and
unirradiated MDC (data not shown). This shift in IL-12/IL-10
production by activated DC after irradiation may affect the Th1/
Th2 balance of the immune response and potentially compromise
antitumour therapy (Clerici et al, 1998; Lappin and Campbell,
2000).
We further examined the impairment in IL-12 production after
irradiation of LPS-matured DC over a range of radiation doses.
Figure 4C shows that over five donors, IL-12 production was
significantly impaired at a dose as low as 2Gy. This falls within the
range of clinical radiotherapy treatment, and increases the
possibility that endogenous DC within treatment fields may be
functionally affected in patients.
Irradiation of peptide-pulsed mature DC impairs naive
CTL priming
To more rigorously test the consequences of irradiation on DC
function, we next examined naı ¨ve T-cell priming against a defined
tumour-associated antigen, MART-1, using peptide-pulsed HLA-
A2þve MDC as the APC (Gattoni-Celli and Cole, 1996); IDC
without activation are ineffective at such priming (Jonuleit et al,
2000). This assay directly tests the ability of DC to activate and
expand a specific effector T-cell population able to lyse antigen-
expressing targets. As shown in Figure 5, MART-1-pulsed MDC
irradiated to 30Gy (a routine procedure in such priming
protocols) were able to prime an antigen-specific naı ¨ve CTL
response. However, when unirradiated MDC were used in these
cultures, more T cells proliferated over the 3-week period of
culture to generate a greater number of effector cells (Figure 5A).
Moreover, these CTL showed higher levels of cytotoxicity, on a per
cell basis, against peptide-pulsed targets. While the absolute
difference in an individual experiment at any effector:target ratio
between lysis by CTL primed with irradiated vs control DC was in
the region of 10%, this difference proved reproducible and
statistically significant across four separate donors (pooled data
shown in Figure 5B). The percentage target lysis of control cells
pulsed with an irrelevant or no peptide was always o30% at
highest 100:1 effector:target ratio (data not shown). These data
suggest that, when using DC as the APC for optimal priming of
naive T cells, irradiation impairs both the number and cytotoxicity
of the effector cells generated.
Irradiation of DC does not effect nuclear translocation of
RelB
The NF-kB/Rel family of proteins are implicated both in the
activation of DC, and in the cellular response to radiation
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Figure 4 Cytokine secretion by activated DC on irradiation. Cytokine
secretion by LPS-activated DC was assayed by ELISA. IL-12 p70 secretion
was significantly reduced on irradiation to 30Gy of DC from five separate
donors (Po0.001) (A), while IL-10 was unaffected (B). Pooled results
show a dose response in IL-12 secretion at 2, 8, and 30Gy (C).
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Figure 5 Priming of a naı ¨ve cytotoxic T-cell response by irradiated DC.
Irradiated (30Gy) or control MDC were pulsed with MART-1 peptide and
incubated with PBMC. T-cell cultures were re-stimulated twice at weekly
intervals and assayed for CTL activity at 21 days. Weekly cell counts
showed less proliferation of T cells incubated with irradiated (’) than
unirradiated (E)D C( A shows a representative donor). CTL lysis of
peptide-pulsed targets was lower in cultures primed with irradiated DC
(square), than untreated controls (diamond) (B). These data are shown as
pooled results of CTL killing of MART-1 pulsed targets for four separate
donors. Unirradiated vs irradiated groups were statistically significant
(Po0.001).
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s(Rescigno et al, 1999; Jung and Dritschilo, 2001). To explore the
mechanism underlying the effects of radiation on DC, we assessed
nuclear translocation of RelB as a marker of DC activation (Pettit
et al, 1997; Oyama et al, 1998). As expected, nuclear RelB was
increased in MDC compared to IDC (Figure 6). Irradiation did not
effect RelB expression in IDC, but interestingly further increased
levels in MDC. Hence, suppression of DC function by irradiation is
not due to interference with nuclear translocation of transcription
factors of the NF-kB pathway on activation.
DISCUSSION
The potential role for DC in tumour immunotherapy is
rapidly expanding in preclinical studies and early patient trials
(Timmerman and Levy, 1999). Both in vitro applications of DC and
in vivo immunotherapy strategies can involve treatment of DC
with ionising radiation, often to high dose. The rationale for ex
vivo DC irradiation is not always clear, but may be designed to
prevent continued DC division or the outgrowth of tumour cell
components of vaccine preparations (Gong et al, 1997; Celluzzi
and Falo, 1998; Szmania et al, 2001). In vivo irradiation of DC may
be incidental during clinical radiotherapy, or part of sequencing
combined modality treatment with immunotherapy (Teitz-
Tennenbaum et al, 2003). Regardless of the in vitro or in vivo
scenario, activation of the immune response by irradiated DC may
be significantly altered. Although UV is known to suppress the
function of some DC subsets (Schmitt and Ullrich, 2000; Denfeld
et al, 2001; Simon et al, 2002; Seite et al, 2003), the effects of
ionising radiation have not been fully elucidated, and are often
assumed to be immunologically neutral.
This study has shown that irradiation of DC significantly affects
their behaviour and functional interaction with responding T cells.
Our first observation was that DC were resistant to radiation, even
following a single high-dose fraction of 30Gy (Figure 1). It should
be noted that in this context resistance applies to radiation-
induced apoptosis and early death, rather than later potential
mitotic cell death as described for dividing cells, with loss of
clonogenicity (Cohen-Jonathan et al, 1999). Some increase in loss
of IDC was seen over time with irradiation, though this was not
statistically significant, and MDC lost viability at identical rates
with or without treatment. Annexin/PI staining showed no
evidence of the early, interphase apoptosis characteristic of
lymphocyte populations (Illidge, 1998). This resistance may reflect
the differentiated state of DC which, apart from IDC over the first
24h, do not proliferate significantly following their initial culture
period. While the mechanisms underlying the effects of radiation
on DC require further exploration, these data show that any
functional changes seen in irradiated DC are not simply due to
rapid cell death.
To characterise the phenotype and function of irradiated human
DC, we used several in vitro assays. Initial experiments measuring
surface expression of DC activation markers revealed limited
changes only. No significant changes were seen in a panel of
surface molecules apart from the co-stimulatory molecule CD86,
whose expression was increased on irradiated IDC, and decreased
on irradiated MDC (Figure 2A–D). This could imply decreased
T-cell stimulatory capacity for irradiated MDC and perhaps some
increase for IDC, although absolute CD86 levels on IDC remained
very low even after 30Gy (MFI range 5–12 for IDC, compared to
164–764 for MDC). On testing in an allogeneic MLR, treatment of
both IDC and MDC led to impairment of T-cell proliferation
(Figure 2E and F), confirming that irradiation impairs T-cell
stimulation by DC, and that factors other than CD86 are involved
in this defective interaction.
Specific T-cell responses against TAA critically depend on the
ability of DC to pick up antigen from their environment and
subsequently track to lymph nodes on activation. We therefore
tested the endocytic and phagocytic capacities of irradiated DC, as
well as their motility on fibronectin-coated plates. For IDC, we
found a limited reduction in endocytic and phagocytic capacities
and a transient increase in motility on irradiation, while MDC
function was unaffected in these assays (Figure 3). Expression of
CCR7 (a chemokine receptor upregulated on DC activation to
facilitate access to lymph nodes) was unaltered by irradiation of
either IDC or MDC (data not shown). This suggests that immune
priming by irradiated DC is unlikely to be significantly affected by
their ability to acquire antigen or access reactive T cells in lymph
nodes.
Although irradiated DC should access T cells in lymph nodes,
additional factors are likely to contribute to the final outcome of
DC/T-cell interaction. DC-derived cytokines are particularly
important in driving a Th1 or Th2 T-cell response, and directing
subsequent immunity towards a cytotoxic or regulatory T-cell bias
(Lappin and Campbell, 2000). We therefore tested cytokine
production in response to DC activation. As shown in Figure 4,
the significant change seen in cytokines on DC irradiation was a
reduction in levels of secreted IL-12. Since IL-12 is a key factor in
priming Th1 responses (Trinchieri, 2003), and Th2 cytokines such
as IL-10 were unaltered, this may influence the Th1/Th2 balance of
immunity primed by irradiated vs unirradiated DC. To explore this
hypothesis further, detailed characterisation of the Th phenotype
of T cells activated by irradiated DC is currently underway in our
laboratory. Interestingly, the reduction in IL-12 production by
irradiated DC was seen at doses as low as 2Gy (Figure 4C), that is,
within the range of daily doses used for clinical therapy. If wide
fields are used during treatments lasting several weeks, this
increases the likelihood that patient DC function may be
significantly affected during radiotherapy.
A critical requirement for DC-stimulated immunity in many
antitumour therapeutic strategies is the generation of an effective
CTL response against defined tumour-associated antigens. CTL
represent a key end point in many protocols which currently
employ irradiated DC as APC, both in vitro and in vivo (Gong et al,
1997; Celluzzi and Falo, 1998; Fields et al, 1998; Szmania et al,
2001). Using MART-1 presented by HLA-A2 as a model antigen,
we have shown that irradiated human DC prime fewer T cells
which are less effective at lysing peptide-pulsed targets (Figure 5).
Clearly, irradiation of DC does not entirely prevent CTL priming,
as significant cytotoxicity was still seen in cultures using irradiated
DC as APC. However, unirradiated DC primed CTL which were
significantly more effective at target lysis in multiple donors, and
across all effector:target ratios tested (Figure 5B). Hence, when
using DC to prime T cells for antitumour immunity, irradiation of
DC may impair, though not eradicate, CTL generation.
Activation of the NF-kB pathway, including nuclear transloca-
tion of the RelB subunit transcription factor, is a central
component of DC activation, and has also been implicated in the
cellular response to radiation (Rescigno et al, 1999). We therefore
tested the effects of DC irradiation on nuclear Rel B expression.
Figure 6 shows that enhanced Rel B translocation in MDC
IDC
IDC 30 Gy
MDC
MDC 30 Gy
Figure 6 Nuclear RelB expression by irradiated dendritic cells. Nuclear
extracts were prepared from irradiated and control IDC and MDC, and
RelB expression analysed by Western blot.
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expression levels were even higher in treated MDC than
unirradiated controls. This suggests that potential mechanisms
underlying suppression of DC function with radiation lie down-
stream of NF-kB activation, and we are currently further
characterising these pathways.
In summary, our data show that irradiation of human DC has
important functional consequences, with differential effects on DC
at different stages of activation. Radiation of immature DC led to
only limited changes in CD86 expression, endocytic/phagocytic
activity and early motility. Although irradiated IDC were
significantly less potent in an MLR, their ability to tolerise (which
has therapeutic implications for the treatment of, for example,
autoimmune disease) is currently unknown. Regarding the role of
MDC in cancer immunotherapy, this work suggests that irradia-
tion of cultured DC should be avoided if maximal cytotoxic/Th1
T-cell activation is to be realised. The consequences of irradiating
endogenous DC in vivo during routine therapy or immunotherapy
protocols may also be significant, although further studies using
clinical material, freshly isolated DC subsets and additional DC
populations involved in immune priming (such as plasmacytoid
DC) are required.
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